Cite
HARVARD Citation
Stock, S. et al. (2019). Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. International journal of cancer. 145 (5), pp. 1312-1324. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Stock, S. et al. (2019). Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. International journal of cancer. 145 (5), pp. 1312-1324. [Online].